Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Inflamm Res ; 70(3): 359-373, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33566171

RESUMEN

OBJECTIVE AND DESIGN: The omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has been reported to suppress inflammation. Pulmonary inflammation can be directly linked to exposure of various occupational and man-made particles leading to pulmonary diseases. Therapeutic treatments are lacking for particle-induced pulmonary inflammation. These studies evaluated DHA as a therapeutic treatment for semi-acute and chronic particle-induced pulmonary inflammation. METHODS: Balb/c mice were oropharyngeal instilled with hydrophobic multi-walled carbon nanotube (MWCNT) or hydrophilic crystalline silica (SiO2) either as one instillation (semi-acute) or once a week for 4 weeks (chronic). One week later, the mice were placed on either a control or 1% DHA-containing diet for 3 weeks (semi-acute) or 12 weeks (chronic). Mice were assessed for inflammatory signaling within the lung lavage fluid, impact on phagolysosomal membrane permeability, shifts of macrophage phenotype gene expression (M1, M2a, M2b, and M2c), and pulmonary histopathology. RESULTS: DHA increased pulmonary inflammatory markers and lung pathology when mice were exposed to SiO2. There were trending decreases of inflammatory markers for MWCNT-exposed mice with DHA treatment, however, mostly not statistically significant. CONCLUSION: The anti-inflammatory benefits of DHA treatment depend upon the type of inflammatory particle, magnitude of inflammation, and duration of treatment.


Asunto(s)
Antiinflamatorios/uso terapéutico , Suplementos Dietéticos , Ácidos Docosahexaenoicos/uso terapéutico , Inflamación/dietoterapia , Enfermedades Pulmonares/dietoterapia , Animales , Células Cultivadas , Citocinas/inmunología , Femenino , Inflamación/inducido químicamente , Inflamación/inmunología , Inflamación/patología , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/patología , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/patología , Macrófagos Alveolares/efectos de los fármacos , Macrófagos Alveolares/inmunología , Masculino , Ratones Endogámicos BALB C , Nanotubos de Carbono , Fenotipo , Dióxido de Silicio
2.
Int J Mol Sci ; 21(9)2020 Apr 28.
Artículo en Inglés | MEDLINE | ID: mdl-32354030

RESUMEN

BACKGROUND: On the 31 December 2019, the World Health Organization (WHO) was informed of a cluster of cases of pneumonia of unknown origin detected in Wuhan City, Hubei Province, China. The infection spread first in China and then in the rest of the world, and on the 11th of March, the WHO declared that COVID-19 was a pandemic. Taking into consideration the mortality rate of COVID-19, about 5-7%, and the percentage of positive patients admitted to intensive care units being 9-11%, it should be mandatory to consider and take all necessary measures to contain the COVID-19 infection. Moreover, given the recent evidence in different hospitals suggesting IL-6 and TNF-α inhibitor drugs as a possible therapy for COVID-19, we aimed to highlight that a dietary intervention could be useful to prevent the infection and/or to ameliorate the outcomes during therapy. Considering that the COVID-19 infection can generate a mild or highly acute respiratory syndrome with a consequent release of pro-inflammatory cytokines, including IL-6 and TNF-α, a dietary regimen modification in order to improve the levels of adiponectin could be very useful both to prevent the infection and to take care of patients, improving their outcomes.


Asunto(s)
Antioxidantes/administración & dosificación , Betacoronavirus , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/terapia , Dieta , Suplementos Dietéticos , Neumonía Viral/inmunología , Neumonía Viral/terapia , Adiponectina/metabolismo , Ácido Ascórbico/administración & dosificación , COVID-19 , Infecciones por Coronavirus/metabolismo , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/metabolismo , Flavonoides/administración & dosificación , Humanos , Interleucina-6/inmunología , Interleucina-6/metabolismo , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/metabolismo , Enfermedades Pulmonares/terapia , Pandemias , Neumonía Viral/metabolismo , SARS-CoV-2 , Factor de Necrosis Tumoral alfa/metabolismo
3.
Nat Immunol ; 20(10): 1279-1290, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31501577

RESUMEN

The revolution in microbiota research over the past decade has provided invaluable knowledge about the function of the microbial species that inhabit the human body. It has become widely accepted that these microorganisms, collectively called 'the microbiota', engage in networks of interactions with each other and with the host that aim to benefit both the microbial members and the mammalian members of this unique ecosystem. The lungs, previously thought to be sterile, are now known to harbor a unique microbiota and, additionally, to be influenced by microbial signals from distal body sites, such as the intestine. Here we review the role of the lung and gut microbiotas in respiratory health and disease and highlight the main pathways of communication that underlie the gut-lung axis.


Asunto(s)
Microbioma Gastrointestinal , Enfermedades Pulmonares/microbiología , Pulmón/microbiología , Microbiota , Probióticos/uso terapéutico , Acinetobacter , Animales , Bifidobacterium , Suplementos Dietéticos , Femenino , Interacciones Huésped-Patógeno , Humanos , Lactobacillus , Pulmón/inmunología , Enfermedades Pulmonares/dietoterapia , Enfermedades Pulmonares/inmunología , Exposición Materna , Embarazo
4.
PLoS Pathog ; 15(8): e1007957, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31437249

RESUMEN

Human zinc deficiency increases susceptibility to bacterial infection. Although zinc supplementation therapies can reduce the impact of disease, the molecular basis for protection remains unclear. Streptococcus pneumoniae is a major cause of bacterial pneumonia, which is prevalent in regions of zinc deficiency. We report that dietary zinc levels dictate the outcome of S. pneumoniae infection in a murine model. Dietary zinc restriction impacts murine tissue zinc levels with distribution post-infection altered, and S. pneumoniae virulence and infection enhanced. Although the activation and infiltration of murine phagocytic cells was not affected by zinc restriction, their efficacy of bacterial control was compromised. S. pneumoniae was shown to be highly sensitive to zinc intoxication, with this process impaired in zinc restricted mice and isolated phagocytic cells. Collectively, these data show how dietary zinc deficiency increases sensitivity to S. pneumoniae infection while revealing a role for zinc as a component of host antimicrobial defences.


Asunto(s)
Suplementos Dietéticos , Modelos Animales de Enfermedad , Enfermedades Pulmonares/inmunología , Infecciones Neumocócicas/inmunología , Streptococcus pneumoniae/inmunología , Virulencia/efectos de los fármacos , Zinc/administración & dosificación , Animales , Femenino , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/microbiología , Ratones , Infecciones Neumocócicas/tratamiento farmacológico , Infecciones Neumocócicas/microbiología , Streptococcus pneumoniae/efectos de los fármacos , Streptococcus pneumoniae/crecimiento & desarrollo
5.
Exp Lung Res ; 45(5-6): 135-150, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31190576

RESUMEN

Abrin, a highly toxic plant protein found in the seeds of Abrus precatorius plant. To date, there is no antidote against abrin intoxication. Abrin is toxic by all routes of exposure, but inhalation exposure is the most toxic of all routes. Present study was conducted to evaluate the acute inhalation toxicity of aerosolized abrin in BALB/c mice. Animals were exposed to 0.2 and 0.8LC50 doses of aerosolized abrin and evaluated at 1 and 3 day post toxin exposure. Bronchoalveolar fluid from lungs was used for evaluation of markers for lung injury. Abrin inhalation exposure caused rise in LDH activity, protein content, increase in ß-glucuronidase and myeloperoxidase activity. Increase in CRP activity, MMP-9 expression and recruitment of CD11b + inflammatory cells in lungs was also observed which was associated with severe inflammation and lung damage. Histopathological findings support the lung damage after abrin exposure. Our results indicate lung injury after single aerosol inhalation exposure, associated with excessive inflammation, oxidative stress, pulmonary edema followed by lung damage. These results could supplement treatment strategies and planning for therapeutic approaches against aerosolized abrin inhalation exposure.


Asunto(s)
Abrina/toxicidad , Exposición por Inhalación/efectos adversos , Enfermedades Pulmonares/inducido químicamente , Pulmón/efectos de los fármacos , Animales , Líquido del Lavado Bronquioalveolar/química , Proteína C-Reactiva/metabolismo , Antígeno CD11b/metabolismo , Catalasa/metabolismo , Glucuronidasa/metabolismo , Glutatión/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Pulmón/enzimología , Pulmón/inmunología , Enfermedades Pulmonares/enzimología , Enfermedades Pulmonares/inmunología , Ratones Endogámicos BALB C , Activación Neutrófila , Peroxidasa/metabolismo
6.
Food Funct ; 10(4): 2209-2220, 2019 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-30945705

RESUMEN

Ginkgo biloba has long been used in ancient China for the treatment of cough, asthma, and other lung diseases. However, the active constituents in G. biloba for pulmonary disease treatment remain unclear. The objective of this study was to evaluate the anti-inflammatory active constituents in G. biloba and clarify their associated molecular mechanisms. The biological effects of different G. biloba extracts were evaluated in an ovalbumin-induced allergic mouse model. Anti-inflammatory compounds were present in the ethyl acetate phase of the extract, which were analysed by HPLC-MS. Biflavones were identified as the main compounds, which were further evaluated by docking calculations. Leukocyte elastase showed a high fit score with ginkgetin, one of the identified biflavones. The lowest binding free energy was -6.69 kcal mol-1. The effects of biflavones were investigated in vivo and in vitro. Ginkgetin markedly suppressed the abnormal expression of the Akt and p38 pathways in human neutrophil elastase (HNE)-stimulated A549 cells. Biflavones also decreased MUC5AC mRNA expression in HNE-stimulated A549 cells and the allergic mouse model. Inflammatory cells (neutrophils) and cytokines (IL-8) also decreased in mice treated with biflavones. The results suggest that G. biloba biflavones could inhibit the activity of leukocyte elastase. This in turn implicates G. biloba as a functional food for the treatment of airway inflammation.


Asunto(s)
Antiinflamatorios/administración & dosificación , Antiinflamatorios/química , Ginkgo biloba/química , Enfermedades Pulmonares/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Animales , Antiinflamatorios/aislamiento & purificación , Biflavonoides/administración & dosificación , Biflavonoides/química , Biflavonoides/aislamiento & purificación , Femenino , Humanos , Interleucina-8/genética , Interleucina-8/inmunología , Enfermedades Pulmonares/genética , Enfermedades Pulmonares/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Mucina 5AC/genética , Mucina 5AC/inmunología , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta/química
7.
Food Chem Toxicol ; 126: 67-71, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30769049

RESUMEN

Aloin is the major anthraquinone glycoside obtained from the Aloe species and exhibits anti-inflammatory and anti-oxidative activities. Here, we aimed to determine the effects of aloin on heme oxygenase-1 (HO-1) induction and on the expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX) 2 in lipopolysaccharide (LPS)-activated human umbilical vein endothelial cells (HUVECs). To the end, aloin was tested whether aloin reduces iNOS protein expression and inflammatory markers (interleukin (IL)-1ß and tumor necrosis factor (TNF)-α) in LPS-treated mice lung tissue. The results indicated that aloin affected HO-1 induction and reduced LPS-activated NF-κB-luciferase activity showed to preferential inhibition of iNOS/NO and COX-2/PGE2 that was partly related to inhibition of STAT-1 phosphorylation. In particular, aloin induced translocation of Nrf2 from cytosol into the nucleus by an increased Nrf2-ARE binding activity, and reduced IL-1ß production in LPS-activated HUVECs. The reduced expression of iNOS/NO by aloin was reversed by siHO-1RNA-transfection. In LPS-treated mice, aloin significantly reduced iNOS protein in lung tissues, and TNF-α levels in the BALF. We concluded that aloin may be beneficial for treatment of lung injury.


Asunto(s)
Antiinflamatorios/administración & dosificación , Emodina/análogos & derivados , Enfermedades Pulmonares/tratamiento farmacológico , FN-kappa B/inmunología , Óxido Nítrico Sintasa de Tipo II/genética , Extractos Vegetales/administración & dosificación , Factor de Transcripción STAT1/inmunología , Animales , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/inmunología , Emodina/administración & dosificación , Hemo-Oxigenasa 1/genética , Hemo-Oxigenasa 1/inmunología , Células Endoteliales de la Vena Umbilical Humana/citología , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/inmunología , Humanos , Enfermedades Pulmonares/genética , Enfermedades Pulmonares/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , FN-kappa B/genética , Óxido Nítrico Sintasa de Tipo II/inmunología , Factor de Transcripción STAT1/genética , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunología
8.
J Med Food ; 21(11): 1096-1105, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29719160

RESUMEN

Propolis is a natural bee product, and it has many effects, including antioxidant, anti-inflammatory, antihepatotoxic, and anticancer activity. In this study, we aimed to explore the potential in vivo anti-inflammatory, antioxidant, and antiapoptotic properties of propolis extract on lipopolysaccharide (LPS)-induced inflammation in rats. Forty-two, 3- to 4-month-old male Sprague Dawley rats were used in six groups. LPS (1 mg/kg) was administered intraperitoneally to rats in inflammation, inflammation + propolis30, and inflammation+propolis90 groups. Thirty milligram/kilogram and 90 mg/kg of propolis were given orally 24 h after LPS injection. After the determination of the inflammation in lung and liver tissues by 18F-fluoro-deoxy-d-glucose-positron emission tomography (18FDG-PET), samples were collected. The levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), nitric oxide (NO), and DNA fragmentation were determined. The decrease of MDA levels in inflammation + propolis30 and inflammation + propolis90 groups was determined compared to the inflammation group in lung and liver tissues. The increase of SOD% inhibition in inflammation + propolis90 group was determined in liver, lung, and hemolysate compared to the inflammation group. Increased CAT activities in inflammation + propolis30 and inflammation + propolis90 groups were observed in liver tissue and hemolysate compared to inflammation group. In lung tissue, NO levels were lower in inflammation group compared to the control group, but DNA fragmentation levels were higher. 18F-FDG uptake of tissues in inflammation + propolis30 and inflammation + propolis90 groups was decreased compared to the inflammation group. In conclusion, the data of this study indicate that the propolis application may serve as a potential approach for treating inflammatory diseases through the effect of reducing inflammation and free oxygen radical production.


Asunto(s)
Catalasa/metabolismo , Endotoxinas/toxicidad , Hepatopatías/inmunología , Hepatopatías/prevención & control , Enfermedades Pulmonares/prevención & control , Própolis/administración & dosificación , Sustancias Protectoras/administración & dosificación , Animales , Humanos , Hígado/efectos de los fármacos , Hígado/inmunología , Hígado/metabolismo , Hepatopatías/etiología , Hepatopatías/metabolismo , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/metabolismo , Enfermedades Pulmonares/etiología , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/metabolismo , Masculino , Malondialdehído/metabolismo , Óxido Nítrico/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Superóxido Dismutasa/metabolismo
9.
Physiol Rev ; 98(3): 1335-1370, 2018 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-29717929

RESUMEN

Airborne pathogens and environmental stimuli evoke immune responses in the lung. It is critical to health that these responses be controlled to prevent tissue damage and the compromise of organ function. Resolution of inflammation is a dynamic process that is coordinated by biochemical and cellular mechanisms. Recently, specialized proresolving mediators (SPMs) have been identified in resolution exudates. These molecules orchestrate anti-inflammatory and proresolving actions that are cell type specific. In this review, we highlight SPM biosynthesis, the influence of SPMs on the innate and adaptive immune responses in the lung, as well as recent insights from SPMs on inflammatory disease pathophysiology. Uncovering these mediators and cellular mechanisms for resolution is providing new windows into physiology and disease pathogenesis.


Asunto(s)
Ácidos Grasos Omega-3/metabolismo , Lipoxinas/metabolismo , Enfermedades Pulmonares/inmunología , Inmunidad Adaptativa , Animales , Humanos , Inmunidad Innata , Enfermedades Pulmonares/metabolismo
10.
Vaccine ; 36(8): 1047-1054, 2018 02 14.
Artículo en Inglés | MEDLINE | ID: mdl-29406241

RESUMEN

Pseudomonas aeruginosa is an opportunistic pathogen responsible for a wide range of severe nosocomial and community acquired infections, these infections are major health problems for cystic fibrosis patients and immune-compromised individuals. The emergence of multidrug-resistant isolates highlights the need to develop alternative strategies for treatment of P. aeruginosa infections. Outer membrane vesicles (OMVs) are spherical nanometer-sized proteolipids that are secreted from numerous of pathogenic Gram-negative bacteria, and a number of studies have confirmed the protective efficacy for use of OMVs as candidate vaccines. In this study, OMVs from P. aeruginosa (PA_OMVs) were isolated, formulated with aluminum phosphate adjuvant and used as a vaccine in a mouse model of acute lung infection. The results confirmed that active immunization with PA_OMVs was able to reduce bacterial colonization, cytokine secretion and tissue damage in the lung tissue, thus protecting mice from lethal challenge of P. aeruginosa. Cytokines assay validated that immunization with PA_OMVs was efficient to induce a mixed cellular immune response in mice. Further, high level of specific antibodies was detected in mice immunized with PA_OMVs, and results from opsonophagocytic killing assay and passive immunization suggested that humoral immune response may be critical for PA_OMVs mediated protection. These findings demonstrated that PA_OMVs may be served as a novel candidate vaccine for the prevention of P. aeruginosa infection.


Asunto(s)
Proteínas Bacterianas/inmunología , Inmunidad Humoral/inmunología , Inmunización Pasiva , Proteínas Ligadas a Lípidos/inmunología , Pseudomonas aeruginosa/inmunología , Vacunación , Adyuvantes Inmunológicos/química , Adyuvantes Inmunológicos/uso terapéutico , Compuestos de Aluminio/química , Compuestos de Aluminio/inmunología , Animales , Proteínas Bacterianas/química , Proteínas Bacterianas/aislamiento & purificación , Femenino , Inmunidad Celular/inmunología , Proteínas Ligadas a Lípidos/química , Proteínas Ligadas a Lípidos/aislamiento & purificación , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/prevención & control , Enfermedades Pulmonares/terapia , Ratones , Ratones Endogámicos BALB C , Fosfatos/química , Fosfatos/inmunología , Infecciones por Pseudomonas/inmunología , Infecciones por Pseudomonas/prevención & control , Infecciones por Pseudomonas/terapia
11.
Nat Med ; 23(9): 1036-1045, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28759052

RESUMEN

D-mannose, a C-2 epimer of glucose, exists naturally in many plants and fruits, and is found in human blood at concentrations less than one-fiftieth of that of glucose. However, although the roles of glucose in T cell metabolism, diabetes and obesity are well characterized, the function of D-mannose in T cell immune responses remains unknown. Here we show that supraphysiological levels of D-mannose safely achievable by drinking-water supplementation suppressed immunopathology in mouse models of autoimmune diabetes and airway inflammation, and increased the proportion of Foxp3+ regulatory T cells (Treg cells) in mice. In vitro, D-mannose stimulated Treg cell differentiation in human and mouse cells by promoting TGF-ß activation, which in turn was mediated by upregulation of integrin αvß8 and reactive oxygen species generated by increased fatty acid oxidation. This previously unrecognized immunoregulatory function of D-mannose may have clinical applications for immunopathology.


Asunto(s)
Colitis/inmunología , Diabetes Mellitus Tipo 1/inmunología , Enfermedades Pulmonares/inmunología , Pulmón/efectos de los fármacos , Manosa/farmacología , Páncreas/efectos de los fármacos , Hipersensibilidad Respiratoria/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Factor de Crecimiento Transformador beta/efectos de los fármacos , Traslado Adoptivo , Animales , Colon/efectos de los fármacos , Suplementos Dietéticos , Modelos Animales de Enfermedad , Ácidos Grasos/metabolismo , Citometría de Flujo , Factores de Transcripción Forkhead/metabolismo , Humanos , Técnicas In Vitro , Inflamación , Integrinas/efectos de los fármacos , Integrinas/inmunología , Metabolismo de los Lípidos/efectos de los fármacos , Pulmón/inmunología , Enfermedades Pulmonares/inducido químicamente , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos NOD , Ovalbúmina/efectos adversos , Oxidación-Reducción/efectos de los fármacos , Páncreas/inmunología , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Hipersensibilidad Respiratoria/inducido químicamente , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Bazo/efectos de los fármacos , Bazo/inmunología , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo , Factor de Crecimiento Transformador beta/inmunología , Regulación hacia Arriba
12.
Mediators Inflamm ; 2016: 2348968, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27445433

RESUMEN

Pulmonary inflammation is a hallmark of many respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory syndrome distress (ARDS). Most of these diseases are treated with anti-inflammatory therapy in order to prevent or to reduce the pulmonary inflammation. Herbal medicine-derived natural products have been used in folk medicine and scientific studies to evaluate the value of these compounds have grown in recent years. Many substances derived from plants have the biological effects in vitro and in vivo, such as flavonoids, alkaloids, and terpenoids. Among the biological activities of natural products derived from plants can be pointed out the anti-inflammatory, antiviral, antiplatelet, antitumor anti-allergic activities, and antioxidant. Although many reports have evaluated the effects of these compounds in experimental models, studies evaluating clinical trials are scarce in the literature. This review aims to emphasize the effects of these different natural products in pulmonary diseases in experimental models and in humans and pointing out some possible mechanisms of action.


Asunto(s)
Productos Biológicos/uso terapéutico , Medicina de Hierbas/métodos , Inflamación/tratamiento farmacológico , Enfermedades Pulmonares/tratamiento farmacológico , Animales , Humanos , Inflamación/inmunología , Enfermedades Pulmonares/inmunología
13.
PLoS One ; 10(11): e0139686, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26599638

RESUMEN

The administration of prebiotics as oligosaccharides (OS), by acting on intestinal microbiota, could modulate the immune and inflammatory response and represent a new strategy to improve the outcome of bacterial infection. The aim of this study was to determine whether pectin-derived acidic oligosaccharides (pAOS) could modulate the outcome of pulmonary P. aeruginosa (PA) infection in C57BL/6 mice, which develop a Th1 response to PA lung infection. Mice were randomized for 5 weeks to consume a control or a 5% pAOS diet and chronically infected by PA. Resistance to a second PA infection was also analyzed by reinfecting the surviving mice 2 weeks after the first infection. Compared with control mice, mice fed pAOS had reduced mortality (P<0.05). This improvement correlated with a better control of the inflammatory response with a lower neutrophil count on day 1 (P<0.05), a sustained neutrophil and macrophage recruitment on days 2 and 3 (P<0.01) a greater and sustained IL-10 release in lung (P<0.05) and a reduction of the Th1 response and M1 activation with a lower IFN-γ/IL-4 (P<0.01) and nos2/arg1 (P<0.05) ratios. These results coincided with a modulation of the intestinal microbiota as shown by an increased butyric acid concentration in feces (P<0.05). Moreover, pAOS decreased the bacterial load (P<0.01) in mice reinfected 2 weeks after the first infection, suggesting that pAOS could reduce pulmonary exacerbations. In conclusion, pAOS improved the outcome of PA infection in C57BL/6 mice by modulating the intestinal microbiota and the inflammatory and immune responses.


Asunto(s)
Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/microbiología , Oligosacáridos/uso terapéutico , Pectinas/química , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/microbiología , Animales , Carga Bacteriana/inmunología , Dieta , Ácidos Grasos Volátiles/metabolismo , Heces/química , Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/inmunología , Masculino , Ratones Endogámicos C57BL , Neumonía/complicaciones , Neumonía/tratamiento farmacológico , Neumonía/inmunología , Neumonía/microbiología , Infecciones por Pseudomonas/complicaciones , Infecciones por Pseudomonas/inmunología , Pseudomonas aeruginosa , Análisis de Supervivencia , Resultado del Tratamiento
14.
Am J Physiol Lung Cell Mol Physiol ; 309(10): L1056-75, 2015 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-26361874

RESUMEN

Disrupted daily or circadian rhythms of lung function and inflammatory responses are common features of chronic airway diseases. At the molecular level these circadian rhythms depend on the activity of an autoregulatory feedback loop oscillator of clock gene transcription factors, including the BMAL1:CLOCK activator complex and the repressors PERIOD and CRYPTOCHROME. The key nuclear receptors and transcription factors REV-ERBα and RORα regulate Bmal1 expression and provide stability to the oscillator. Circadian clock dysfunction is implicated in both immune and inflammatory responses to environmental, inflammatory, and infectious agents. Molecular clock function is altered by exposomes, tobacco smoke, lipopolysaccharide, hyperoxia, allergens, bleomycin, as well as bacterial and viral infections. The deacetylase Sirtuin 1 (SIRT1) regulates the timing of the clock through acetylation of BMAL1 and PER2 and controls the clock-dependent functions, which can also be affected by environmental stressors. Environmental agents and redox modulation may alter the levels of REV-ERBα and RORα in lung tissue in association with a heightened DNA damage response, cellular senescence, and inflammation. A reciprocal relationship exists between the molecular clock and immune/inflammatory responses in the lungs. Molecular clock function in lung cells may be used as a biomarker of disease severity and exacerbations or for assessing the efficacy of chronotherapy for disease management. Here, we provide a comprehensive overview of clock-controlled cellular and molecular functions in the lungs and highlight the repercussions of clock disruption on the pathophysiology of chronic airway diseases and their exacerbations. Furthermore, we highlight the potential for the molecular clock as a novel chronopharmacological target for the management of lung pathophysiology.


Asunto(s)
Ritmo Circadiano , Enfermedades Pulmonares/metabolismo , Pulmón/metabolismo , Animales , Proteínas CLOCK/fisiología , Senescencia Celular , Regulación de la Expresión Génica/inmunología , Humanos , Pulmón/inmunología , Pulmón/patología , Enfermedades Pulmonares/inmunología , Oxidación-Reducción
15.
Inhal Toxicol ; 27(10): 451-61, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26307905

RESUMEN

The concept of microbial content of the lung is still controversial. What make this more complicated are controversial results obtaining from different methodologies about lung microbiome and the definition of "lung sterility". Lungs may have very low bacteria but are not completely germ-free. Bacteria are constantly entering from the upper respiratory tract, but are then quickly being cleared. We can find bacterial DNA in the lungs, but it is much harder to ask about living bacteria. Here, we propose that if there is any trafficking of the microorganisms in the lung, it should be a "Transient But Not Resident (TBNR)" model. So, we speculate a "Yin Yang model" for the lung immune system and TBNR. Despite beneficial roles of microbiome on the development of lung immune system, any disruption and alteration in the microbiota composition of upper and lower airways may trigger or lead to several diseases such as asthma, chronic obstructive pulmonary disease and mustard lung disease.


Asunto(s)
Pulmón/inmunología , Pulmón/microbiología , Microbiota , Animales , Humanos , Sistema Inmunológico , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/microbiología , Yin-Yang
16.
J Infect Dis ; 211(1): 156-65, 2015 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-25139019

RESUMEN

BACKGROUND: A predominantly T-helper type 2 (Th2) immune response is critical in the prognosis of pulmonary Pseudomonas aeruginosa infection. But the mucosal and systemic immune responses can be influenced by the intestinal microbiota. METHODS: We assessed the effect of microbiota compositional changes induced by a diet enriched in 5% acidic oligosaccharides derived from pectin (pAOS) on the immune response and outcome of chronic pulmonary P. aeruginosa infection in mice. RESULTS: pAOS promoted Th1 polarization by increasing interferon γ release, upregulating t-bet gene expression, decreasing interleukin 4 secretion, and downregulating gata3 gene expression. pAOS also sustained the release of keratinocyte chemoattractant, recruited polynuclear leukocytes and macrophages, stimulated M1 macrophage activation and interleukin 10 release, and decreased tumor necrosis factor α release in the lung. These effects led to increased bacterial clearance after the first and second P. aeruginosa infections. pAOS modified the intestinal microbiota by stimulating the growth of species involved in immunity development, such as Bifidobacterium species, Sutturella wadsworthia, and Clostridium cluster XIVa organisms, and at the same time increased the production of butyrate and propionate. CONCLUSION: These results suggest that pAOS may have beneficial effects by limiting the number and severity of pulmonary exacerbations in patients chronically infected with P. aeruginosa, such as individuals with cystic fibrosis.


Asunto(s)
Intestinos/efectos de los fármacos , Intestinos/microbiología , Enfermedades Pulmonares/tratamiento farmacológico , Microbiota/efectos de los fármacos , Oligosacáridos/farmacología , Pectinas/química , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Animales , Factores Quimiotácticos/inmunología , Factor de Transcripción GATA3/inmunología , Interferón gamma/inmunología , Interleucina-10/inmunología , Interleucina-4/inmunología , Intestinos/inmunología , Queratinocitos/inmunología , Queratinocitos/microbiología , Leucocitos/inmunología , Leucocitos/microbiología , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/microbiología , Macrófagos/inmunología , Macrófagos/microbiología , Masculino , Ratones , Ratones Endogámicos BALB C , Microbiota/inmunología , Infecciones por Pseudomonas/inmunología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/crecimiento & desarrollo , Proteínas de Dominio T Box/inmunología , Células TH1/inmunología , Células TH1/microbiología , Factor de Necrosis Tumoral alfa/inmunología
17.
J Interferon Cytokine Res ; 34(11): 902-14, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25051168

RESUMEN

Formalin-inactivated respiratory syncytial virus (FI-RSV) immunization is known to cause severe pulmonary inflammatory disease after subsequent RSV infection. Ginseng has been used in humans for thousands of years due to its potential health benefits. We investigated whether ginseng would have immune modulating effects on RSV infection in mice previously immunized with FI-RSV. Oral administration of mice with ginseng increased IgG2a isotype antibody responses to FI-RSV immunization, indicating T-helper type 1 (Th1) immune responses. Ginseng-treated mice that were nonimmunized or previously immunized with FI-RSV showed improved protection against RSV challenge compared with control mice without ginseng treatment. Ginseng-mediated improved clinical outcomes after live RSV infection were evidenced by diminished weight losses, decreased interleukin-4 cytokine production but increased interferon-γ production, modulation of CD3 T-cell populations toward a Th1 response, and reduced inflammatory response. Ginseng-mediated protective host immune modulation against RSV pulmonary inflammation was observed in different strains of wild-type and mutant mice. These results indicate that ginseng can modulate host immune responses to FI-RSV immunization and RSV infection, resulting in protective effects against pulmonary inflammatory disease.


Asunto(s)
Enfermedades Pulmonares/prevención & control , Panax/inmunología , Extractos Vegetales/administración & dosificación , Infecciones por Virus Sincitial Respiratorio/prevención & control , Vacunas contra Virus Sincitial Respiratorio/efectos adversos , Virus Sincitiales Respiratorios/inmunología , Animales , Femenino , Formaldehído/química , Células Hep G2 , Humanos , Inmunización/efectos adversos , Inmunoglobulina G/sangre , Inmunomodulación , Interferón gamma/metabolismo , Interleucina-4/metabolismo , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/virología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Extractos Vegetales/inmunología , Raíces de Plantas/inmunología , Infecciones por Virus Sincitial Respiratorio/inmunología , Vacunas contra Virus Sincitial Respiratorio/administración & dosificación , Virus Sincitiales Respiratorios/química , Células TH1/efectos de los fármacos , Células TH1/inmunología , Vacunas de Productos Inactivados/efectos adversos
18.
Mediators Inflamm ; 2013: 751068, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23737654

RESUMEN

The physiology and pathology of the respiratory and gastrointestinal tracts are closely related. This similarity between the two organs may underlie why dysfunction in one organ may induce illness in the other. For example, smoking is a major risk factor for COPD and IBD and increases the risk of developing Crohn's disease. Probiotics have been defined as "live microorganisms which, when administered in adequate amounts, confer health benefits on the host." In model systems probiotics regulate innate and inflammatory immune responses. Commonly used probiotics include lactic acid bacteria, particularly Lactobacillus, Bifidobacterium, and Saccharomyces, and these are often used as dietary supplements to provide a health benefit in gastrointestinal diseases including infections, inflammatory bowel disease, and colon cancer. In this respect, probiotics probably act as immunomodulatory agents and activators of host defence pathways which suggest that they could influence disease severity and incidence at sites distal to the gut. There is increasing evidence that orally delivered probiotics are able to regulate immune responses in the respiratory system. This review provides an overview of the possible role of probiotics and their mechanisms of action in the prevention and treatment of respiratory diseases.


Asunto(s)
Probióticos/uso terapéutico , Bifidobacterium/fisiología , Tracto Gastrointestinal/microbiología , Humanos , Factores Inmunológicos/uso terapéutico , Lactobacillus/fisiología , Enfermedades Pulmonares/inmunología , Enfermedades Pulmonares/microbiología , Enfermedades Pulmonares/prevención & control , Enfermedades Respiratorias/inmunología , Enfermedades Respiratorias/microbiología , Enfermedades Respiratorias/prevención & control , Saccharomyces/fisiología
19.
Paediatr Respir Rev ; 14(4): 236-41, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23462434

RESUMEN

The management of rheumatic conditions, including those occurring in children, has improved dramatically over the last decade following the introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDS) into the therapeutic arsenal. The benefits have been realised in multiple aspects of disease including signs and symptoms, bone and cartilage destruction, disability and quality of life. Overall, bDMARDS have an acceptable safety profile in the short to medium term in adults and children, however, that following longer term use remains unclear. As these drugs target key signalling molecules and cells of the immune system, adverse events are not unanticipated. In this review we will discuss pulmonary complications of biologic therapies used in the management of rheumatic diseases in both children and adults.


Asunto(s)
Antirreumáticos/efectos adversos , Factores Biológicos/efectos adversos , Terapia Biológica/efectos adversos , Sistema Inmunológico/efectos de los fármacos , Enfermedades Pulmonares , Enfermedades Reumáticas/tratamiento farmacológico , Adulto , Antirreumáticos/uso terapéutico , Factores Biológicos/uso terapéutico , Niño , Salud Global , Humanos , Incidencia , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/epidemiología , Enfermedades Pulmonares/inmunología , Enfermedades Reumáticas/inmunología , Adulto Joven
20.
J Tradit Chin Med ; 33(6): 743-51, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24660605

RESUMEN

OBJECTIVE: To investigate the curative effects of Xuebijing (XBJ) injection, a Chinese patent medicine, on severe pulmonary contusion (PC). METHODS: Sixty-three patients with PC were randomized to conventional therapy plus XBJ injection (n = 33) or conventional therapy alone (n = 30). Between groups differences in corticosteroid treatment, immune regulation therapy, hemofiltration, infusion volume, transfusion volume and antibiotic period were measured, as were intensive care unit (ICU)-free time, ventilation time, 28-day mortality rate and incidence of ventilation-associated pneumonia (VAP). Serum concentrations of procalcitonin (PCT), tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-10, white blood cell (WBC) counts and percentages of human leukocyte antigen DR/ CD14+ (HLA-DR/CD14+) peripheral blood mononuclear cells were compared. Markers of ventilation were determined by blood gas analysis and ventilator parameters. RESULTS: WBC counts and serum concentrations of PCT, TNF-alpha, IL-6 and IL-10 were reduced significantly more quickly, and CD14+ percentage was increased significantly earlier, in the XBJ group than in the control group (P < 0.05 each).The level of ventilation and oxygenation index were ameliorated earlier in the XBJ than in the control group (P < 0.05). XBJ treatment significantly reduced ICU-free time, ventilation time and incidence of VAP (P < 0.05 each), but had no effect on 28-day mortality rate CONCLUSION: XBJ treatment can shorten ICU-free and ventilation times and reduce the incidence of VAP, improving outcomes in patients with severe PC. XBJ may act by regulating inflammation and immunity, alleviating systemic inflammatory response syndrome induced by trauma.


Asunto(s)
Contusiones/tratamiento farmacológico , Medicamentos Herbarios Chinos/administración & dosificación , Enfermedades Pulmonares/tratamiento farmacológico , Adolescente , Adulto , Contusiones/sangre , Contusiones/inmunología , Femenino , Humanos , Interleucina-10/sangre , Interleucina-6/sangre , Enfermedades Pulmonares/sangre , Enfermedades Pulmonares/inmunología , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/sangre , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA